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Abstract 
AMD3100, also known as plerixafor, was originally developed as an anti-human immunodeficiency virus (HIV) drug, 
and later characterized as a C-X-C chemokine receptor type 4 (CXCR4) antagonist. Previous reviews have focused on 
the application of AMD3100 in the treatment of HIV, but a comprehensive evaluation of AMD3100 in the treatment 
of leukemia, solid tumor, and diagnosis is lacking. In this review, we broadly describe AMD3100, including the back-
ground, functional mechanism and clinical applications. Until the late 1990s, CXCR4 was known as a crucial factor 
for hematopoietic stem and progenitor cell (HSPC) retention in bone marrow. Subsequently, the action and synergy 
of plerixafor with Granulocyte-colony stimulating factor (G-CSF) led to the clinical approval of plerixafor as the first 
compound for mobilization of HSPCs. The amount of HSPC mobilization and the rapid kinetics promoted additional 
clinical uses. Recently, CXCR4/CXCL12 (C-X-C motif chemokine 12) axis was found to be involved in a variety of roles 
in tumors, including leukemic stem cell (LSC) homing and signaling transduction. Thus, CXCR4 targeting has been a 
treatment strategy against leukemia and solid tumors. Understanding this mechanism will help shed light on thera-
peutic potential for HIV infection, inflammatory diseases, stem-cell mobilization, leukemia, and solid tumors. Clarifying 
the CXCR4/CXCL12 axis and role of AMD3100 will help remove malignant cells from the bone marrow niche, render-
ing them more accessible to targeted therapeutic agents.
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Background
In 1981, the US Centers for Disease Control and Pre-
vention (CDC) published the first official report on the 
acquired immune deficiency syndrome (AIDS) epidemic. 
The identification of human immunodeficiency virus 
(HIV) as the causative agent for AIDS in 1985 spurred 
a massive search for inhibitors of the retrovirus. Rozen-
baum et  al. [1] reported in  vivo efficacy of a polyoxo-
metalate, HPA-23, that inhibited HIV levels in patients 
with AIDS. This evidence triggered a search for other 
analogues more effective in suppressing HIV levels. 
In 1990, De Clercq et  al. [2] (the pioneer of AMD3100, 
from Rega Institute of Leuven, Belgium), in collabora-
tion with investigators at Johnson Matthey, discovered 
bicyclam JM1657 (JM; Johnson Matthey) as an active 
anti-HIV agent. Attempts to re-synthesize JM1657 failed, 
but a new analogue of JM3100, later renamed AMD3100 
(AMD; AnorMED, spun off from Johnson Matthey) was 
successfully synthesized in 1994 [3]. They found AMD 
3100 inhibited HIV within a 1–10 nM range. The mecha-
nism of action was thought to be the inhibition of viral 
replication at the time.
Leading up to 1996, Donzella et  al. [4] and Schols 
et  al. [5] demonstrated that AMD3100 blocks HIV-1 
entry and membrane fusion via specific targeting of the 
C-X-C chemokine receptor type 4 (CXCR4) co-recep-
tor of the T-lymphotropic X4 strain (Fig.  1). It was not 
active against the M-macrophage tropic R5 strains, 
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which are a CCR5-using population. These in vivo stud-
ies highlighted the effectiveness of AMD3100 against X4 
HIV-1 infection. In 1996, Datema et al. [6] first demon-
strated AMD3100 efficacy in severe combined immu-
nodeficiency (SCID)-hu Thy/Liv mice infected with a 
clinical isolate of X4 HIV-1. Small animal in vivo results 
encouraged Phase I/II clinical studies. In 2000, Hendrix 
et  al. [7] first reported the pharmacokinetics and safety 
of AMD3100 in human volunteers. These clinical data 
clearly showed AMD3100 effective in suppressing X4 
HIV-1 levels in HIV-1-infected individuals.
During clinical trials, reduced X4 HIV-1 levels in 
HIV-infected volunteers were observed, as expected [8]. 
However, researchers noticed elevated white blood cell 
(WBC) counts. This unexpected observation was later 
translated in AMD3100 as an application to mobilize 
hematopoietic stem cells (HSCs). In 2006, Genzyme Cor-
poration completed its acquisition of AnorMED (Fig. 1). 
Phase I studies demonstrated that AMD3100 had mini-
mal side effects and effectively mobilized CD34+ HSC in 
both healthy volunteers and patients heavily pretreated 
with anti-tumor drugs. Phase II results built a compelling 
case of efficacy and safety. Two phase III, multicenter, 
double-blind, randomized, and placebo-controlled 
studies compared the safety and efficacy of AMD3100. 
Together, these trials provided sufficient evidence for 
the US Food and Drug Administration (FDA) approval 
of plerixafor (Mozobil, Genzyme Corp.; AMD3100) in 
2008 (Fig. 1). AMD3100 proved an extremely specific and 
effective CXCR4 antagonist. However, AMD3100 is not 
limited to mobilization of HSCs. It is also used for a vari-
ety of disorders that depend on the interplay of CXCR4 
with its agonist CXCL12 (also called: SDF-1) including 
leukemia and breast cancer.
Molecular pharmacology of AMD3100 in blocking 
CXCR4
AMD3100 is strongly basic at physiological PH due to 
four primary amines in each cyclam ring. X-ray data 
show the protonated cyclam ring has a tendency to form 
complexes with carboxylic acid groups via hydrogen 
bonds [9].
CXCR4 belongs to the largest family of proteins in the 
human genome, named seven transmembrane spanning 
receptors (7TM receptors) (Fig. 2a). Schwartz et al. [10] 
described activation of 7TM receptors in the Global Tog-
gle Switch Model (Fig.  3). The crystal structure of the 
inactive and active states of CXCR4 was vital information 
in understanding 7TM receptor activation. In 2008, Park 
and Scheerer et al. [11, 12] provided strong evidence to 
the switch theory by crystalizing rhodopsin, presumed 
to be an active state representation. This crystal struc-
ture demonstrated that compared to the inactive state, 
the cytoplasmic half of transmembrane domain VI (TM-
VI) is tilted outwardly away from the helical bundle by 
6–7 Å. In 2010, the first crystal structure of CXCR4 was 
described by Stevens and coworkers [13]. The authors 
described the distinct differences between the structure 
of CXCR4 and other published crystal structure of 7TM.
Crystal structure data proved to be powerful, but lim-
ited in that they are snapshots of the inactive or active 
states, not sufficient when describing the dynamic pro-
cess of activation. Therefore, functional receptor studies 
were needed. Several studies focused on the negatively 
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Fig. 1 Timeline of major discoveries that shaped our understanding of AMD3100 and its practical use
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charged domains of AMD3100 facing the binding pocket 
of CXCR4. In 2011, Gerlach et  al. [14] performed a 
mutagenesis study of all aspartate residues facing the 
binding pocket of CXCR4. By testing all the mutants in 
competition binding, two aspartate residues were found 
in the extracellular ends of TM-IV (Asp171) and TM-VI 
(Asp262) associated with binding of AMD3100. These 
findings led to a proposal of the interaction model, in 
which AMD3100 spans the ligand-binding pocket and 
each cyclam ring binds to aspartate residues located at 
the extracellular ends of TM. Rosenkilde et al. [15] con-
ducted comprehensive mutational substitutions of 16 
residues located in TM-III, TM-IV, TM-VI, and TM-
VII of CXCR4. They found AMD3100 not only depends 
strongly on two aspartate residues, as previously men-
tioned (Asp171 and Asp262), but also a glutamate (Glu288) 
in TM-VII. The combination of three acidic residues is a 
unique structure to CXCR4, which explains AMD3100′s 
high selectivity [16]. Given that mutational analysis did 
not reveal which side chains, or surrounding amino acids 
in proximity with the aromatic linker, are involved in 
AMD3100-interactions, a binding model of AMD3100 
was suggested. The hypothesis suggests one cyclam ring 
interacts with the aspartate in TM-IV, while the other is 
located between the aspartate in TM-VI and the gluta-
mate in TM-VII. The linker then acts as a constraint, pre-




To date, only two compounds have been approved by the 
FDA to modulate chemokines and their receptors. CCR5 
antagonist maraviroc (Celsentri) is an HIV entry inhibitor 
approved in 2007. CXCR4 antagonist AMD3100 (Mozo-
bil) was approved in 2008. Originally, AMD3100 was 
developed for treating HIV infections [17]. HIV enters 
the host cell through an interaction between envelope 
protein (gp120) and the host chemokine receptors, CCR5 










AMD3100 [64Cu]AMD3100  
Fig. 2 Chemical structure of AMD3100 and [64Cu]AMD3100
Fig. 3 Schematic drawing of the 7TM receptor activation mechanism as proposed by the Global Toggle Switch Model
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as R5-tropic viruses, those using CXCR4 receptors are 
known as R4-tropic viruses, and those using both recep-
tors are known as dual-tropic viruses. AMD3100 relies 
on the bicyclams to block the interaction between gp120 
and CXCR4 [6]. The original clinical studies evaluated the 
efficacy of AMD3100 as an anti-HIV treatment modality 
[7]. However, continuous daily dosing requirements were 
impractical. Moreover, side effects were found including 
cardiac arrhythmia in two patients. AMD3100 is not cur-
rently being pursued for the treatment of HIV infections 
given dosing difficulty, side effects and lack of effect [18].
Stem cell mobilization
Hematopoietic stem cell transplantation (HSCT) is 
increasingly used in the treatment of a variety of hema-
tological malignancies and nonmalignant diseases such 
as sickle cell disease, autoimmune disease, and bone mar-
row failure. Currently, the use of mobilized peripheral 
blood HSC has replaced collection from pelvic bone mar-
row due to several reasons. First, the collection of periph-
eral HSC is less invasive. Second, there is a higher yield 
of HSC and progenitor cells collected from mobilized 
peripheral blood compared with bone marrow harvests. 
Third, there is significantly less toxicity and incidence of 
serious complications after peripheral blood stem cell 
transplantation (PBSCT) compared with bone marrow 
transplantation [19].
The mobilization procedure in normal donors requires 
administration of granulocyte-colony-stimulating fac-
tor (G-CSF). However, it causes significant side effects 
including bone pain, headaches and splenic rupture [20]. 
More importantly, G-CSF does not mobilize adequate 
numbers to safely undergo transplantation in a propor-
tion of cases, particularly those with previous pretreat-
ment of chemotherapy. AMD3100 is the only CXCR4 
antagonist currently approved for HSC mobilization. 
Clinical data show less toxicity compared with HIV infec-
tions given the short time frame of administration of 
AMD3100 to initiate mobilization of hematopoietic stem 
and progenitors (HSPCs). Broxmeyer et  al. [21] con-
ducted the first proof-of principle studies on mobiliza-
tion of HSPC in mice with AMD3100. The results were 
successfully translated by Dr. Dale’s group into human 
volunteers [22]. Mobilization of HSC and HPC in mice 
and humans is much quicker with AMD3100 (in min-
utes to hours) compared with G-CSF (days). Moreover, 
AMD3100 enhances mobilization of HPC in mouse mod-
els of genetic disease associated with “poor” response to 
G-CSF-induced mobilization [23].
The mechanism of AMD3100-induced mobilization 
involves the CXCR4/CXCL12 axis. The well-charac-
terized mechanism of cell adhesion involves a CXCR4/
CXCL12 interaction. This pathway was first discovered in 
the 1990s with a description of the chemokine CXCL12, 
and further explored in the hematopoiesis system [24, 
25]. The CXCR4 is a G-protein-coupled receptor. After 
binding to its exclusive ligand CXCL12, CXCR4 activates 
several signaling cascades that trigger intracellular cal-
cium release and phosphorylation of ERK 1/2. Current 
evidence indicates adhesion or mobilization of HSPC is 
dependent on CXCL12 concentrations in the blood and 
the bone marrow that act via CXCR4 signaling [26]. In 
addition, CXCR4 is considered more of a signaling recep-
tor than an adhesion molecule. CXCL12 can be viewed as 
a chemokine directing cell movement. Dar et al. [26] also 
described CXCL12 homoeostasis in AMD3100-induced 
mobilization, showing AMD3100 administration reduced 
levels of CXCL12 signaling and the retention signals 
within the BM, also leading to an increased CXCL12-con-
centration in the peripheral blood. AMD3100 induced 
CXCL12 release is supported by in vitro results showing 
release of CXCL12 from osteoblasts and endothelial cells 
after incubation with AMD3100.
Application of AMD3100 in leukemia
Hematopoietic cancer stem cells express the CXCR4 
receptor. In conjunction with its CXCL12 ligand, CXCR4 
mediates leukemia cell trafficking and homing to the 
bone marrow microenvironment in close proximity to 
marrow stromal cells. This provides a niche for leukemic 
cell growth and contributes to drug resistance. The use 
of CXCR4 antagonists may provide a novel therapeutic 
approach to interrupt these protective interactions and 
sensitize leukemia cells to chemotherapy in vivo.
Treatment of acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is characterized by 
monoclonal and/or oligoclonal proliferation of hemat-
opoietic lymphoid precursor cells within bone marrow 
[27, 28]. Advances in childhood treatment have been 
achieved with over 80  % of individuals cured. However, 
a poor prognosis is expected for patients with different 
risk factors, such as relapses and central nervous system 
side effects [29]. Shen et  al. [30] and Spiegel et  al. [31] 
demonstrated down regulation of CXCR4 results in sig-
nificant inhibition of ALL cell homing to the bone mar-
row (Fig.  4). CXCR4/CXCL12 axis plays an important 
role in the infiltration of extramedullary sites, which 
commonly express high levels of CXCL12, supported 
by the evidence of high expression of CXCR4 in all cells 
and extramedullary organ invasiveness [32]. In addi-
tion to the crucial role in migration, studies indicate that 
CXCL12 is involved in the pathogenesis of ALL, includ-
ing facilitating metastasis, mobilizing tumor cells, and 
attracting of cancer stem cells within the tumor microen-
vironment [33, 34]. Moreover, CXCR4/CXCL12 signaling 
Page 5 of 11Liu et al. Exp Hematol Oncol  (2016) 5:19 
has been investigated extensively in activating multiple 
molecules, including PI3  K-Akt, MAPK and JAK-STAT 
signaling pathways [35]. Thus, it is reasonable that ALL 
subsets would benefit from the therapeutic strategy of 
CXCR4/CXCL12 axis. Indeed, Hatse et  al. [16] showed 
that AMD3100 inhibited CXCR4 internalization and 
chemotaxis of ALL cells. Kato et  al. [36] developed a 
therapeutic model where AMD3100 prevented relapse 
of extramedullary ALL cells after chemotherapy. These 
studies indicate that AMD3100 perturbs the mainte-
nance of leukemic cells and/or leukemic stem cells in the 
bone marrow, prolonging exposure of chemotherapeutic 
agents in the peripheral blood. In addition, AMD3100 
increases the proportion of leukemic cells in the circula-
tion that are actively cycling [37].
Treatment of chronic lymphocytic leukemia
CXCR4 is expressed at high levels on the surface of 
peripheral blood chronic lymphocytic leukemia (CLL) 
cells [38]. Functionally, CXCR4 mediates CLL cell chemo-
taxis, migration across vascular endothelium, and migra-
tion beneath and underneath bone marrow stromal cells 
(BMSCs) that secrete CXCL12, termed “pseudoemperi-
polesis” [39, 40]. In addition, CXCR4 is involved in CLL 
cell migration and homing to tissue niches. Clinically, this 
function may be involved in drug-resistance and minimal 
residual disease (MRD), evidenced by the fact that CLL 
cells become highly resistant to conventional cytotoxic 
drugs when cultured in the presence of BMSC [41, 42]. 
Stromal cell niches in the bone marrow may provide pro-
tection where CLL cells are immune from chemother-
apy, accounting for MRD and relapses after current CLL 
therapies [43]. Burger et  al. [41] reported that CXCR4 
antagonists inhibited CLL cell activation by CXCL12, 
and prohibited BMSC-mediated drug resistance. There-
fore, the phase I trial of AMD3100 in combination with 
rituximab in CLL volunteers was initiated to determine 
the maximum tolerated dose (MTD) and the principal 
toxicities. Similar to AML, CML, and CLL, blockage of 
the CXCR4/CXCL12 pathway by AMD3100 is also being 
investigated in multiple myeloma and other hematopoi-
etic cancers.
Treatment of acute myelogenous leukemia
The association of acute myelogenous leukemia (AML) 
cells with the bone marrow microenvironment may be 
mediated by CXCR4, which is invariably expressed on 
AML blasts [24]. Tavor et al. [44] found that pretreating 
human AML cells with neutralizing CXCR4 antibodies 
inhibited their homing and retention in the bone mar-
row of transplanted NOD/SCID/β2m mice. This sug-
gests the CXCR4/CXCL12 axis is a target for anti-AML 
therapies. In a 122 AML patient chemotherapy study, 
Konoplev et al. [45] found high CXCR4 expression corre-
lated with shorter overall survival and shorter event-free 
survival. Prompted by these observations, Uy et  al. [46] 
Fig. 4 CXCR4/CXCL12 signaling in homing of hematopoietic stem cell (HSCs), CML leukemic stem cell (LSCs), and malignant B cells (i.e., CLL cells) 
to the bone marrow microenvironment. The perivascular niche is composed of a network of sinusoids (red) and adjacent reticular stromal cells 
niche (green) that constitutively secrete CXCL12. a In CML, LSCs (red cells) may exploit the same mechanism as HSCs (brown cells) to access niche. 
CXCR4/CXCL12-mediated interactions sheltered LSCs from the cytotoxic effects of TKIs. Interruption of CXCR4/CXCL12 interaction by AMD3100 may 
promote expulsion of quiescent LSCs from their niche and render them more accessible to targeted therapeutic agents. b In CLL, both HSCs and 
CLL cells express CXCL4, which directs chemotaxis of hematopoietic progenitor cells (HPC) and CLL from the circulation to the bone marrow. Malig-
nant B cells (blue cells) utilize the CXCR4/CXCL12 axis to access niche that normally are restricted to HSC. This niche microenvironment will create 
favorable condition for their survival (such as fibronectin and hyaluronan) and provide survival, drug resistance signals to the CLL cells. Interruption 
of CXCR4/CXCL12 interaction by AMD3100 may promote expulsion of malignant B cells from bone marrow niche and render them more accessible 
to targeted therapeutic agents
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conducted a phase I/II study of 52 patients with relapsed 
or refractory AML and determined the extent to which 
AMD3100 mobilized leukemic cells. These encourag-
ing data promoted randomized phase III clinical trials 
in patients with relapsed AML to determine the role of 
CXCR4 blocking in improving complete remission rates 
in these high-risk patients.
The approach of combinational use of AMD3100 with MER 
kinase inhibitor to improve anti‑tumor drug efficacy in the 
context of acute myelogenous leukemia
MERTK (TAM) family of receptor tyrosine kinases 
(RTKs) are aberrantly expressed in multiple haemato-
logical and epithelial malignancies. Targeting MERTK 
is a promising strategy in the treatment of AML. For 
example, the small molecule UNC2025, discovered by 
Dr. Graham, specifically targets MERTK and FMS-like 
tyrosine kinase 3 (FLT3) and was developed in preclini-
cal phase for the treatment of ALL and AML [47]. How-
ever, chronic and sustained inhibition of TAM family 
RTKs have deleterious side effects, such as autoimmun-
ity and retinitis. Relapse and drug resistance are the main 
obstacles for UNC2025. In order to reduce AML relapse, 
we expect AMD3100 to be combined with UNC2025 to 
optimize the drug efficacy. The following procedure has 
potential: couple UNC2025 with CXCR4-targeted lipid-
coated ploy (lactic-co-glycolic acid (PLGA) nanoparticles 
(NPs) modified with a CXCR4 antagonist; AMD3100 
will systemically deliver UNC2025 into bone marrow 
LSC and sensitize LSC to UNC2025 treatment (Fig.  5). 
AMD3100 attached to the NPs will also block CXCR4/
CXCL12, reducing infiltration of tumor-associated mac-
rophages, enhancing the anti-angiogenic effect.
Treatment of chronic myeloid leukemia
Tyrosine kinase inhibitor (TKI) based therapy has 
improved clinical outcomes in chronic myeloid leukemia 
(CML). Imatinib (Gleevec), an ABL TKI, is highly effec-
tive in newly diagnosed CML patients, with complete 
cytogenetic responses in more than 80  % of cases [48]. 
Although the targeted therapy elicits durable remissions 
it does not eradicate leukemic stem cells (LSCs), the res-
ervoir of CML. In 2006, Krause et al. [49] demonstrated 
homing and engraftment of CML LSCs is characterized 
by dependence on the CD44 receptor and reduced reli-
ance on CXCR4 and its ligand, CXCL12 (Fig. 4).
Given the reduced importance of CXCR4/CXCL12 in 
CML compared with normal HSCs, and CXCR4 antag-
onists are potential therapeutics for treatment of CML, 
the particular application that captures our attention is 
the recurrence of active leukemia. TKI-based therapy 
restores CXCR4/CXCL12 dependent trafficking and 
homing of CML LSCs to bone marrow [50]. Perturbation 
of the CXCR4/CXCL12 interaction with AMD3100 pro-
motes egress of CML LSCs and progenitor cells from the 
bone marrow niche, potentially increasing their suscep-
tibility to targeted strategies currently being evaluated in 
clinical trials.
Fig. 5 AMD3100 systemically deliver UNC2025 into bone marrow LSC and sensitize LSC to UNC2025 treatment
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Treatment of other type of leukemia
KMT2A gene, also known as mixed lineage leukemia 
(MLL) gene, encodes a lysine (K) specific histone meth-
yltransferase 2A [51]. This enzyme contributes to the 
S-phase DNA damage checkpoint [52]. Rearrangements 
of the MLL gene were found in 5.2 % of all the AML cases 
and in 22  % of all cases [53]. Patients with MLL rear-
rangements have poor prognosis and shorter overall sur-
vival rates [54]. However, the mechanism leading to its 
rearrangement is still unclear. Given that half of patients 
recur with a short latency to relapse suggests that chem-
otherapy-resistant leukemia stem cells survive and reca-
pitulate leukemia. The use of AMD3100 led to markedly 
enhanced efficacy with lestaurtinib [55]. Therefore, the 
bone marrow microenvironment is a mediator of chemo-
therapy resistance in MLL and targeting leukemia stem 
cell-niche cell interactions with AMD3100 would benefit 
the high-risk subtype of pediatric ALL.
Collectively, CXCR4 antagonists offer a new tool to 
mobilize leukemia cells from their protective bone mar-
row niche. AMD3100 is being explored in proof-of-
principle studies in leukemia patients where leukemia 
cell mobilization can be assessed. Given the expression 
of functional CXCR4 receptors by a variety of other 
hematopoietic cancers and solid tumors, broader use of 
AMD3100 is the long-term goal.
Application of AMD3100 in solid tumors
Breast cancer is the most commonly diagnosed malig-
nancy in women worldwide [56]. Development of meta-
static breast cancer is responsible for the majority of 
cancer-related deaths. Muller et  al. [57] demonstrated 
that CXCR4 is expressed in human breast cancer cells 
and metastatic lesions. This evidence first identified a key 
function of CXCR4/CXCL12 in metastatic breast can-
cer. Many organs such as bone, lung, and liver express 
high levels of CXCL12, and are commonly affected by 
metastatic breast cancer. Kang et al. [58] injected human 
breast cancer cells in mice and found they preferentially 
formed bone metastases.
The CXCR4 signaling pathway facilitates breast can-
cer cell survival, proliferation, chemotaxis, invasion and 
adhesion. CXCL12 binding to CXCR4 stimulates the 
phosphatidylinositol-3-kinase pathway that subsequently 
activates the Akt pathway, facilitating growth factor-
mediated cell survival and apoptosis suppression [59]. 
Akt also affects CXCR4 during proliferation of cells and 
migration toward chemotactic cytokine CXCL12 [60, 61]. 
In addition, mitogen-activated protein kinase pathway 
(MAP kinase pathway) is another signaling pathway regu-
lated by CXCR4 that promotes proliferation and survival 
of cancer cells [62]. Moreover, CXCR4 in breast cancer 
activates Janus kinase/signal transducer and activator of 
transcription (JAK/STAT) pathway [63], src family [64], 
and angiogenesis [65]. Together, these pathways facilitate 
migration, invasion and metastasis.
These results are promising for developing a role for 
CXCR4 blockade in the treatment of breast cancer. A 
phase I/II study of AMD3100 in patients with breast can-
cer indicated preliminary signs of efficacy [66]. The use of 
AMD3100 in the treatment of bone metastases could be 
exploited in patients for targeted treatment with CXCR4 
blockade. However, concern was raised regarding side 
effect on the normal hematopoietic balance in the bone 
marrow [67].
Studies also show that CXCL12 promotes pancreatic 
β-cell survival via activation of Akt [68]. These findings 
suggest AMD3100 agonists may prove beneficial for 
treatment of diabetes and lung cancer.
Use of [64Cu]AMD3100 in molecular imaging of CXCR4 
expressed tumors
CXCR4 is overexpressed in 23 different cancers [69]. 
Jacobson et  al. [70] first showed the radiochemical syn-
thesis and evaluation of [64Cu]AMD3100 as a possible 
PET imaging agent (Fig.  2b). They verified that [64Cu]
AMD3100 was as potent AMD3100 as a CXCR4 inhibi-
tor. Recently, [(67)Ga]-AMD3100 [71] and [(99m)Tc]
O2-AMD3100 [72] were also developed as tracers for 
CXCR4 receptor imaging. However, the success of [64Cu]
AMD3100-based imaging agents requires detailed char-
acterization of the changes of CXCR4 and CXCL12 
expression profiles in tumors, metastases, and normal 
tissue distributions.
Conclusion
The development of bicyclam AMD3100 follows a mean-
dering pathway, starting from a serendipitous discovery 
of an impurity in a commercial cyclam preparation to 
its original development as an HIV entry inhibitor, and 
finally leading to an FDA approved product, AMD3100, 
in the application of stem cell mobilization. Potential 
clinical applications of AMD3100 are currently being 
evaluated in several trials with great promise. The advan-
tages of AMD3100 over other CXCR4 antagonists are 
listed in Table 1.
The success of AMD3100 follows the typical pathway 
of drug discovery process that involves identification of 
target, screening process, lead development, and then 
preclinical trials. The following steps are essential to ful-
fill the final approval of AMD3100. First, an illustration 
of a detailed molecular pharmacology of AMD3100 in 
blocking CXCR4 is needed. Second, an understanding 
of the role of CXCR4/CXCL12 axis interaction in the 
HSC’s homing and engraftment is demonstrated. Thus, 
AMD3100 provided a novel strategy to enhance donor 
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cell engraftment and recovery following transplanta-
tion. Third, understand how the CXCR4/CXCL12 axis 
is involved in tumor functions, such as how LSC homing 
and signaling transduction helped translate findings into 
additional clinical uses in leukemia and solid tumors.
AMD3100 has demonstrated clinical efficacy in the 
context of mobilization of HSCs and HPCs, and triggered 
other clinical uses with great promise. One critical rea-
son is that AMD3100 is not species specific, thus stud-
ies of AMD3100 in mouse, canine, monkey, and cell lines 
have translated into human clinical studies quickly. How-
ever, researchers need to consider that circadian rhythms 
influence circulating levels of HSCs and HPSs [73]. It is 
critical to control the timing of AMD3100 administration 
in the context of therapeutic use. In addition, side effects 
after long-term administration add potential problems. 
Shorter-term usage and lower dose would be fundamen-
tal keys to the success in clinical use.
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